Community Health Systems Misses Q2 Revenue, Widens Adjusted Loss, and Lowers Full-Year Outlook
CYH sits 26% above its 52-week low of $2.385.
Summary
Community Health Systems missed Q2 revenue estimates, reported a wider adjusted loss, and lowered full-year guidance, reflecting ongoing pressure from divestitures and cost inflation despite same-store volume gains.
Key Events · Earnings and Guidance · CYH
-
Q2 Revenue Miss
Net operating revenues of $2.825 billion fell 9.8% year-over-year and missed the $2.88 billion consensus, driven by hospital divestitures and unfavorable payor mix.
-
Adjusted Loss Widens
Adjusted net loss per share was $(0.19), compared to $(0.05) in Q2 2025, as higher medical specialist fees and divestiture impacts offset same-store volume growth.
-
Full-Year Guidance Cut
2026 Adjusted EBITDA guidance lowered to $1.3–$1.375 billion, and net loss per share now expected at $(1.25)–$(1.10), reflecting sustained operational headwinds.
-
Cash Flow Deterioration
Net cash used in operating activities was $(209) million for the first six months of 2026, a sharp reversal from $208 million provided in the prior-year period.
Analysis · CYH · Industrial Applications And Services
Community Health Systems delivered Q2 revenue of $2.825 billion, missing the $2.88 billion consensus and declining 9.8% year-over-year. The adjusted net loss per share widened to $(0.19) from $(0.05) a year ago, pressured by divestitures, an unfavorable payor mix, and rising specialist fees. Full-year Adjusted EBITDA guidance was slashed to $1.3–$1.375 billion, with the company now projecting a net loss of $(1.25)–$(1.10) per share. Although same-store volumes posted modest gains, the top-line contraction and deteriorating profitability point to deepening operational challenges. Negative free cash flow in the first half and a heavy debt load further strain financial flexibility.
At the time of this filing, CYH was trading at $3.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $453.8M. The 52-week trading range was $2.39 to $4.43. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.